Zenflow will use the series A funds to trial a minimally invasive device designed to treat urinary symptoms in patients with enlarged prostates.

The algorithm provides a strong model for identifying people with diabetes but has yet to prove itself against the tougher task of spotting undiagnosed…

The collaboration gives Medopad access to the nearly 1 billion users of Tencent’s WeChat messaging service.

Empatica picked up an FDA 510(k) clearance for Embrace after the device detected every seizure in a 135-patient clinical trial.

Cam Med is working on a patch pump as an alternative to traditional insulin pumps in "artificial pancreas" systems.

InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.

Intarcia halted a pair of phase 3 trials, but they are not required for the FDA to approve its drug-device diabetes treatment.

Here's Monday's medtech news of note.